Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IPO Year: 2010
Exchange: NASDAQ
Website: ironwoodpharma.com
Peers
Recent Analyst Ratings for Ironwood Pharmaceuticals Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/15/2025 | Buy → Hold | Jefferies | |
| 4/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 9/9/2024 | $5.00 | Market Perform | Leerink Partners |
| 8/8/2024 | $12.00 → $4.00 | Overweight → Equal Weight | CapitalOne |
| 1/17/2024 | $21.00 | Buy | Craig Hallum |
| 12/14/2023 | $20.00 | Overweight | Wells Fargo |
| 11/9/2023 | $21.00 | Buy | Jefferies |
| 9/28/2023 | $22.00 | Mkt Outperform | JMP Securities |
| 9/2/2022 | $15.00 | Overweight | CapitalOne |
Ironwood Pharmaceuticals Inc. Press Releases
Fastest customizable press release news feed in the world
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full first quarte
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first completed Phase III study in this patient population – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present real-world data during the 2025 Digestive Disease Week® (DDW) meeting, taking place May 3-6 in San Diego, CA. These data will focus on the adoption and utilization of recently approved ICD-10 (International Statist
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval – – Company has engaged Goldman Sachs & Co. LLC to explore strategic alternatives – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral sup
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Ironwood Pharmaceuticals, Inc. (the "Company") (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the "Notice") on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K") with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires Nasdaq-listed
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March
Millrose Properties Set to Join S&P SmallCap 600
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and red
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company
Ironwood Pharmaceuticals Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ironwood Pharma downgraded by Wells Fargo
Wells Fargo downgraded Ironwood Pharma from Overweight to Equal Weight
Ironwood Pharma downgraded by Jefferies
Jefferies downgraded Ironwood Pharma from Buy to Hold
Ironwood Pharma downgraded by Citizens JMP
Citizens JMP downgraded Ironwood Pharma from Mkt Outperform to Mkt Perform
Leerink Partners initiated coverage on Ironwood Pharma with a new price target
Leerink Partners initiated coverage of Ironwood Pharma with a rating of Market Perform and set a new price target of $5.00
Ironwood Pharma downgraded by CapitalOne with a new price target
CapitalOne downgraded Ironwood Pharma from Overweight to Equal Weight and set a new price target of $4.00 from $12.00 previously
Craig Hallum initiated coverage on Ironwood Pharma with a new price target
Craig Hallum initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
Wells Fargo initiated coverage on Ironwood Pharma with a new price target
Wells Fargo initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $20.00
Jefferies initiated coverage on Ironwood Pharma with a new price target
Jefferies initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
JMP Securities initiated coverage on Ironwood Pharma with a new price target
JMP Securities initiated coverage of Ironwood Pharma with a rating of Mkt Outperform and set a new price target of $22.00
CapitalOne initiated coverage on Ironwood Pharma with a new price target
CapitalOne initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $15.00
Ironwood Pharmaceuticals Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Ironwood Pharmaceuticals Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Denner Alexander J was granted 10,416 shares, increasing direct ownership by 7% to 166,769 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
New insider Gaskins Tammi L claimed ownership of 245,159 shares (SEC Form 3)
3 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Chief Executive Officer Mccourt Thomas A sold $244,753 worth of shares (139,064 units at $1.76), decreasing direct ownership by 11% to 1,160,634 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Principal Accounting Officer Silver Ronald sold $21,204 worth of shares (12,048 units at $1.76), decreasing direct ownership by 4% to 279,655 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
SVP, CMO, Head-Res&Drug Shetzline Michael sold $72,633 worth of shares (41,269 units at $1.76) and was granted 133,333 shares, increasing direct ownership by 20% to 554,007 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Chief Legal Officer John Minardo was granted 122,222 shares and sold $68,531 worth of shares (38,938 units at $1.76), increasing direct ownership by 26% to 408,132 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Chief Financial Officer Martini Gregory S. sold $21,212 worth of shares (12,052 units at $1.76), decreasing direct ownership by 6% to 183,810 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Principal Accounting Officer Silver Ronald was granted 133,333 shares, increasing direct ownership by 84% to 291,703 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Chief Financial Officer Martini Gregory S. was granted 111,111 shares, increasing direct ownership by 131% to 195,862 units (SEC Form 4)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
New insider Martini Gregory S. claimed ownership of 84,751 shares (SEC Form 3)
3 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Ironwood Pharmaceuticals Inc. SEC Filings
Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
SEC Form 10-K filed by Ironwood Pharmaceuticals Inc.
10-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.
SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form NT 10-K filed by Ironwood Pharmaceuticals Inc.
NT 10-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.
SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form 144 filed by Ironwood Pharmaceuticals Inc.
144 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SCHEDULE 13G filed by Ironwood Pharmaceuticals Inc.
SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Ironwood Pharmaceuticals Inc. Leadership Updates
Live Leadership Updates
Millrose Properties Set to Join S&P SmallCap 600
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to
Memo Therapeutics AG appoints Paul Carter as Chairperson
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l
Ironwood Pharmaceuticals Announces Leadership Updates
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step down as senior vice president and chief financial officer, effective July 2, 2021, in order to pursue another leadership opportunity at a rare disease biotechnology company. Ms. Consylman’
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
– LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents – – Maintaining full year 2021 financial guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2021 results and recent business performance. "We are off to a solid start to the year, as LINZESS continued the strong momentum we saw in 2020," said Tom M
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent. “We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to adva
Ironwood Pharmaceuticals Inc. Financials
Live finance-specific insights
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 8, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 22, 2024. To listen
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD) – – LINZESS® (linaclotide) EUTRx prescription demand growth of 10% year-over-year – – Revises FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its first quarter 2024 results and recent business performance. "In the
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 3416473. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursday, May 9, 2024 at ap
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week – – Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies of apraglutide in this patient population – – Ironwood to submit new drug application and other regulatory filings for apraglutide as a once-weekly GLP-2 analog for use in adult patients with SBS who are dependent on PS – – Ironwood to host conference
Ironwood Pharmaceuticals Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.
SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc. (Amendment)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc. (Amendment)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc. (Amendment)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc. (Amendment)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc. (Amendment)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)